Lansoprazole Capsule, Delayed Release
Product Images NDC 55111-398

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 55111-398). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

Packaging label for Lansoprazole Delayed-Release Capsules USP, 15 mg, manufactured by Dr. Reddy's Laboratories Limited. The label indicates a unit-dose package containing 10 capsules (1 x 10 unit-dose). It includes storage instructions, product identification marks (RDY and LAN), and a note that the package is not child-resistant. The label features the Dr. Reddy's logo and NDC 55111-398-79.*

FDA Label Image

Carton2 (Carton2)

Packaging label for Lansoprazole delayed-release capsules USP 30 mg, in a carton containing 10 capsules (1 x 10 unit-dose). The label displays the generic name, strength, dosage form, and indicates it is Rx only. It provides storage instructions and warns to keep out of children's reach. The labeler is Dr. Reddy's Laboratories Limited, with an address in India. A barcode and NDC 55111-399-79 are also visible.*

FDA Label Image

Container1 (Container1)

Label for Lansoprazole Delayed-Release Capsules, USP 15 mg by Dr. Reddy's Laboratories Limited, showing a 90-capsule package. The label includes dosage form, strength, quantity, a barcode, and directions to a medication guide online.*

FDA Label Image

Container2 (Container2)

Label for Lansoprazole Delayed-Release Capsules, USP 30 mg, a bulk ingredient packaged by Dr. Reddy's Laboratories Limited. The label indicates 90 capsules, includes NDC 55111-399-90, and features instructions for dispensing with a Medication Guide, a QR code link to the guide, barcode, and storage conditions at 20-25°C.*

FDA Label Image

Figure1 (Figure1)

A line graph showing mean severity of day heartburn by study day for evaluable patients, comparing placebo, lansoprazole 15 mg QD, and lansoprazole 30 mg QD. The y-axis represents mean severity levels from 0 (none) to 3 (severe), and the x-axis shows days from start of treatment, ranging from -5 to 60 days. The graph illustrates decreasing heartburn severity over time with lansoprazole versus placebo.*

FDA Label Image

Figure2 (Figure2)

A line graph showing the mean severity of night heartburn over time in days for patients receiving placebo, lansoprazole 15 mg once daily, and lansoprazole 30 mg once daily. The y-axis represents mean severity levels from 0 (none) to 3 (severe), and the x-axis shows days from the start of treatment up to 60 days. The graph compares symptom severity trends across these treatment groups.*

FDA Label Image

Structure (Structure)

Chemical structure of lansoprazole showing its molecular composition with heterocyclic rings and functional groups, consistent with its use as a delayed release capsule active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.